Hanada et al. reported that asparagine depletion (following a combination of asparagine synthetase deletion and L-asparaginase therapy) combined with EIPA treatment suppressed tumor growth in KRAS-mutant CRC cells (Hanada et al., 2021). This evidence concerns the gene KRAS and neoplasm.